William Blair Investment Management LLC Has $10.91 Million Holdings in Cencora, Inc. $COR

William Blair Investment Management LLC decreased its position in shares of Cencora, Inc. (NYSE:CORFree Report) by 7.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,905 shares of the company’s stock after selling 2,760 shares during the quarter. William Blair Investment Management LLC’s holdings in Cencora were worth $10,909,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of COR. IAG Wealth Partners LLC bought a new stake in shares of Cencora during the third quarter worth about $30,000. Cloud Capital Management LLC acquired a new stake in Cencora during the 3rd quarter worth approximately $31,000. Caitlin John LLC bought a new stake in Cencora during the 3rd quarter worth approximately $31,000. Vermillion & White Wealth Management Group LLC raised its stake in shares of Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after acquiring an additional 43 shares during the last quarter. Finally, Westside Investment Management Inc. grew its stake in shares of Cencora by 200.0% in the third quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock worth $33,000 after purchasing an additional 70 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 15,220 shares of company stock worth $5,282,867. 0.38% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Mizuho raised their target price on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. UBS Group raised their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Evercore decreased their target price on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Bank of America reduced their price objective on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. Finally, Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $399.00.

View Our Latest Research Report on Cencora

Cencora Trading Down 0.3%

COR opened at $371.48 on Wednesday. The company has a fifty day moving average price of $353.00 and a two-hundred day moving average price of $335.29. Cencora, Inc. has a 1-year low of $248.59 and a 1-year high of $377.54. The company has a market cap of $72.26 billion, a P/E ratio of 44.65, a price-to-earnings-growth ratio of 1.74 and a beta of 0.68. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:CORGet Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. During the same period last year, the business posted $3.73 EPS. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. Analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were given a $0.60 dividend. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 annualized dividend and a yield of 0.6%. Cencora’s dividend payout ratio (DPR) is presently 28.85%.

About Cencora

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Featured Stories

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:CORFree Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.